We propose that genes that scored at all steps of our pipeline (Subset 3 at S3 Table) are the most attractive targets for treatment of human cancers with RB1-deficiency and more likely to kill RB1-deficient cells in highly heterogeneous tumor cells. This evidence concerns the gene RB1 and cancer.